Probiotics for Oral Candidiasis: Critical Appraisal of the Evidence and a Path Forward

Linda S. Archambault and Anna Dongari-Bagtzoglou

Oropharyngeal Candidiasis (OPC) is a mucosal fungal infection that is prevalent among patients with compromised immunity. The success of probiotics in treating chronic diseases with a microbial etiology component at other mucosal sites (i.e., gastro-intestinal, genitourinary and alveolar mucosae) has inspired research into the use of probiotics in the treatment of OPC. A growing body of research in vitro and in animal models indicates that some probiotic species and strains have inhibitory activities against Candida albicans growth, morphological switching, and biofilm formation. However, recent review and meta-analysis studies reveal a dearth of human randomized, controlled clinical trials on the efficacy of probiotics to treat or prevent OPC, while the majority of these have not based their selection of probiotic strains or the type of administration on sound pre-clinical evidence. In this mini-review, we assess the state of the field, outline some of the difficulties in translating lab results to clinical efficacy, and make recommendations for future research needed in order to move the field forward.

Keywords: Candida, oropharyngeal candidiasis, probiotics, Lactobacillus, clinical trials, preclinical models

INTRODUCTION

Oropharyngeal Candidiasis (OPC) is a common fungal infection affecting populations with immature or weakened immune systems including neonates, the elderly, AIDS patients, and those taking immunosuppressive drugs [1–4]. Like other diseases in which commensal microbes become pathogenic, OPC is associated with a dysbiotic state, an alteration in the composition or abundance of the oral health-associated host microbiota, contributing to a permissive environment for Candida spp. infection [5, 6]. An aging population, the rise in the use of immune-compromising treatments and the increasing prevalence of drug-resistant Candida strains make it necessary to find alternative treatments for OPC.

Probiotics are defined by the FAO/WHO as “live microorganisms which, when consumed in appropriate amounts in food, confer a health benefit on the host” [7]. Their use is believed to discourage pathogenic microbes and help the host microbiota to return to a health-associated, balanced state after disruptions [8]. Research has provided evidence supporting a positive role of some probiotic organisms in promoting gut, oral and vaginal health, but clinical studies showing no effect of probiotics also exist [9–11].

In this mini-review we explore the current evidence for the role of probiotics in the prevention and treatment of OPC. We will not summarize all work in this area, a task well-accomplished by recent systematic reviews [9, 12–14]. Rather, our intention is to critically appraise the state of the science on this topic by integrating the information gleaned from studies in vitro and in animal
models with the results of human clinical trials, where possible. We discuss the pitfalls of each type of research and the difficulties encountered in translating results from laboratory research to benefits for patients, then suggest areas that need more research attention in the future.

WHAT CAN WE LEARN FROM CLINICAL TRIALS?

Three recent systematic review and meta-analysis studies explored probiotics as treatment or prevention for OPC [15–17]. These studies restricted their analyses to randomized, controlled clinical trials (RCTs) which measured Candida burdens in colony-forming units (CFUs) from saliva samples or swabs of oral mucosal tissues. The meta-analyses included between 3 [18–20] and 8 clinical trials [21–25] that compared a probiotic to a control or placebo. All three meta-analyses found significant reduction in Candida counts in the oral environment as a result of probiotic treatment, although this did not always lead to significant clinical improvements. This suggests that the development of probiotic approaches holds promise in changing current clinical guidelines of OPC prevention or treatment, especially for immunocompromised patients and for patients with refractory or recurring infections.

Bacterial Species Tested as Probiotics in Clinical Trials and Basis for Their Selection

Ideally, when probiotic strains are chosen for clinical trials involving OPC, it would be on the basis of experimental results, either in vitro, or in animal models, or both, that demonstrate their activity against Candida species. Typically, research begins with in vitro studies on the interactions between probiotic species and Candida species, proceeds to in vivo animal model studies to examine aspects of the interaction between probiotics, Candida, and the host, and then moves on to human clinical trials of the probiotic species that show promise. However, probiotics in fermented foods have been part of the human diet since ancient times and scientific study into the clinical benefits of probiotic bacteria for human health began in the late 19th century when scientific methods of inquiry were not well-developed [26]. In addition, much of the early work in the study of probiotics to treat or prevent disease has focused on gastro-intestinal conditions [27]. Because of their presumed safety and benefits in intestinal mucosal diseases, some probiotic species have been tested in humans for their ability to prevent OPC without any prior experimental evidence supporting their anti-Candida activities [18, 22].

The justification behind the choice of probiotic species and strains was specified in 6 of the 8 RCTs covered by the 3 meta-analyses. Commercial probiotic preparations usually contain several species of bacteria, thus clinical trials often use a mixture of species or strains. Lactobacillus species were included in all but one of the RCTs. L. rhamnosus was the most commonly included species (4 studies) and L. reuteri, L. acidophilus, and L. bulgaricus were each used in 2 studies. Additional species in probiotic mixtures included Bifidobacterium longum, Bifidobacterium bifidum, Propionibacterium freudenreichii, and Streptococcus thermophilus. In two of the studies, no reason was provided for the choice of probiotic species or strain [22, 24]. Two of the RCTs used a mixture of 2 strains of L. reuteri [20, 25] citing this species’ production of the antibacterial toxin reuterin and its ability to inhibit the in vitro growth of many Candida spp. [28]. L. rhamnosus Lr32 and L. acidophilus NCFM, which were compared in Miyazima et al. [23], had been previously found to reduce oral C. albicans numbers in an immunocompromised mouse model [29] and to disrupt C. albicans biofilms in vitro [30]. This same group conducted a RCT of a commercial, three-species mixture of L. rhamnosus HS111, L. acidophilus HS 101 and Bifidobacterium bifidum [19], citing studies that tested these and other Lactobacillus species against Candida growth in vitro [31, 32]. In one study intended to improve dental caries incidence in children, Streptococcus salivarius was chosen for its antagonism with S. mutans [21]; changes in both Candida and S. mutans numbers were recorded because of the known synergistic roles of these 2 organisms in dental caries [33, 34]. However, in this study, there was no significant difference in Candida oral burdens between probiotic treatment and placebo. To explain their choice of probiotic species, Hatakka and colleagues [18] cited a successful clinical trial which measured gastrointestinal colonization of Candida in neonates given L. rhamnosus GG [35] and a mouse study which found that probiotic treatment with either Propionibacterium JS or L. rhamnosus GG increased the proliferation of T- and B-cells [36]. The third strain in their study, L. rhamnosus LC705, was used in combination with Propionibacterium JS, which is a preservative against yeast in food manufacture [18]. Thus, it appears that justification for the use of specific probiotic strains in existing RCTs is variable, and the majority of these studies were not based on strong experimental in vitro evidence or on results with preclinical animal models of oral infection.

Few research groups have progressively investigated the same probiotic species in vitro, in an animal model, and in human clinical trials. One such group first found each of 2 Lactobacillus strains, L. rhamnosus LR32 and L. acidophilus NCFM, to be effective against OPC in an immunocompromised mouse model [29]. They then showed the ability of the same strains to interfere with adhesion and hyphal growth in the early stages of C. albicans biofilm formation in vitro [30]. In the ensuing human clinical trial, both strains reduced the oral Candida levels in denture wearers, one (LR32) performing even better than the positive control drug Nystatin [23]. The same group tested a commercial product containing different strains of the same two species, L. rhamnosus HS111 and L. acidophilus HS 101, in a successful clinical trial in denture-wearers [19]. These results however were not reproduced independently by a different group and have not led to widespread implementation of these probiotics in clinical practice.

Lactobacillus rhamnosus GG (LrGG) was patented for use as a probiotic in 1989 and there is an extensive body of clinical research justifying claims of its health benefits, mostly in the treatment of gastro-intestinal disorders [37, 38]. Many of the characteristics that make it promising as a probiotic for gut ailments could apply to the oral environment—it adheres to
epithelial cells, promotes type 1 immune response, reduces inflammation by inhibiting macrophage activation and increases production of IL-10, IL-12 and TNFα in innate immune cells [37]. A great deal of in vitro and in vivo laboratory work has delved into the mechanisms behind this strain’s ability to inhibit potentially pathogenic organisms directly and through its influence on host immune responses [37]. LrGG inhibits C. albicans adhesion and morphological changes [39], induces metabolic reprogramming by nutrient limitation [40], and may break down cell-wall components [41]. LrGG also reduces oral Candida counts in immunocompromised mice [42]. Although there is strong experimental and preclinical evidence supporting the potential efficacy of this strain in limiting OPC, it was used in only one of the above listed RCTs and then, only in combination with other species [18]. More RCTs should provide independent support for the benefits of this probiotic strain in the context of OPC treatment or prevention in humans.

Choosing the Best Probiotics for the Oral Environment

While these clinical and laboratory studies are good first steps, it is evident that in order to make progress in the development of probiotics-based new therapies or prevention strategies for patients who are most susceptible to OPC, we will need to approach scientific inquiry in a more systematic way. This process should include more in vitro work to screen potential probiotics for their activity against Candida species and examine mechanisms of anti-fungal activity. Some criteria for a good probiotic for the treatment of intestinal illness (i.e., the ability to withstand the acid environment of the stomach, be metabolically active under the low oxygen tension in the gut, or to attach to intestinal epithelial cells) may not apply to the oral environment. In choosing the best probiotics for the oral environment, in vitro experiments are needed to explore attachment to oral epithelial cells and the ability to colonize the oral mucosa. It is also important to isolate, identify and test metabolites produced by effective species as these postbiotics could prevent OPC without the risks associated with introducing live organisms in immunocompromised patients who make up most of the susceptible populations [43]. Animal models that recapitulate the different host susceptibility states (i.e., immunocompromised, elderly, cancer patients) will be needed to discover the best probiotic species for each condition and also to test a variety of delivery methods.

PITFALLS IN TRANSLATING LABORATORY FINDINGS TO CLINICAL TRIALS

Experimental work has provided evidence of several anti-Candida activities of Lactobacillus spp. that negatively affect C. albicans virulence characteristics including growth, yeast to hyphae transition, adhesion, and biofilm development [44, 45]. Antifungal mechanisms include production of acids, hydrogen peroxide, bacteriocins, and biosurfactants, as well as competition for adhesion sites. Probiotics can also activate protective functions of the immune system, affecting cytokine profiles, innate and adaptive immune responses, and Candida recognition by epithelial and immune cells [44, 45]. However, which of these protective mechanisms are active in the human oral environment is not fully understood. In the oral environment some of the probiotic protective functions may be compromised by dietary habits and nutrient availability, antagonistic interactions with a complex resident microbiota, and the salivary flow which may limit colonization and persistence.

With respect to persistence in the oral cavity, the impact of probiotic consumption on the oral microbiome is relatively unexplored. The question of whether probiotic organisms become stably incorporated into the human host oral microbiome is not often addressed in clinical trials. However, there is some evidence that while ingested organisms are often detected in the oral cavity of participants during probiotic treatment, they do not persist once treatment ceases [24, 46]. Nevertheless, because OPC is precipitated by an underlying dysbiosis in the oral microbiome [5, 6], it would be important to demonstrate that probiotics can encourage the recovery of a “healthy” microbiome in the oral environment after disruptions caused by antibiotics, cancer treatment or chronic disease, as they appear to do in the gut [8]. These important questions are beginning to be explored using next generation sequencing technology [47, 48] and require more investigation using preclinical models of infection.

It is clear that complex interactions between the fungus, the resident microbiota and the host immune system determine whether C. albicans remains commensal or becomes pathogenic in the oral environment [49, 50]. T helper-17 (Th17) cell-mediated immunity is crucial in maintaining commensal colonization of the oral mucosa by C. albicans [51, 52]. The host aryl hydrocarbon receptor (AhR) binds ligands that are products of tryptophan catabolism and activates IL-17/IL-22 production by Th17 cells. Lactobacilli metabolize tryptophan to produce an AhR ligand, indole-3-aldehyde, which triggers IL-22 production to protect from C. albicans infection and dampen inflammation [53]. Further exploration in this area is needed to reveal how probiotic organisms contribute to metabolic control of protective immune responses in the oral environment.

The effects of probiotic organisms on epithelial barrier function and host immunity have been extensively studied in the context of gastro-intestinal diseases [11, 54]. Probiotics affect host immunity at both the local and systemic levels. Systemic immune effects of probiotic consumption could influence the host’s ability to control Candida in the oral environment without the requirement for probiotic organisms to take up residence there. For example, consumption of Lactobacillus strains in mice was tied to improvement in the function of both peritoneal and alveolar macrophages and protection against both lung and peritoneal infection by C. albicans [55]. These distant protective effects may extend to the oral environment.

Experimental evidence suggests that probiotic organisms prime epithelial and immune cells to respond differently to Candida challenge. Pretreatment with Lactobacillus strains before exposure to C. albicans causes changes in cytokine production and pattern recognition receptor expression in macrophages [56]. In epithelial (HeLa) cell lines, pretreatment...
with \textit{L. crispatus} altered β-defensin and cytokine production and toll-like receptor expression in response to \textit{C. albicans} [57]. To shed light on the role of probiotics in the oral environment, more work must be done using oral epithelial cell lines, primary epithelial cells and mucosal organotypic cultures [58]. It will also be important to differentiate between direct effects of the probiotic organisms on epithelial tissues vs. effects secondary to \textit{Candida} growth and morphology, which can also alter immune responses [59].

**THE PATH FORWARD: DEVELOPING BETTER-TARGETED PROBIOTICS-BASED APPROACHES**

Evidence from RCT meta-analyses suggests that probiotic treatments may work better in preventing OPC, compared to treating established infection in susceptible patient categories [15–17]. This may indicate that short-term administration of probiotics cannot lead to changes in the oral microbiota that are sufficient in magnitude or duration to treat this infection. Interestingly, in these meta-analyses when studies that involved elderly patients or denture wearers were considered separately [18–20, 23], a stronger beneficial effect was found compared to including all studies and all susceptible patient groups together [15, 16]. A recent RCT, not included in the meta-analyses, confirmed this trend [60]. In other patient populations (children and adults), oral \textit{Candida} numbers showed low or no responsiveness to probiotic treatments [21, 24, 25]. This evidence suggests that probiotics must be better targeted to specific vulnerable populations such as patients who are HIV positive, undergoing cancer treatment, or taking immunosuppressive drugs. In vivo animal models mimicking these conditions may be useful in developing a better-targeted, host immune susceptibility type-combined with a specific probiotic strain approach in treatment or prevention.

In the 8 RCTs mentioned above, the dose, timing, duration and delivery methods for probiotics were varied. Doses in adult populations ranged from $7.2 \times 10^7$ to $2 \times 10^{10}$ CFUs per day. To put these numbers in perspective, a dosage of $10^{10}$ CFU per day was required to colonize the digestive tract and to treat acute gastroenteritis in children [61, 62], suggesting that better outcomes might have been achieved with higher doses in OPC studies with adults. Delivery methods included lozenges, cheese, yogurt, milk and the application of probiotic organisms directly onto denture surfaces. The timing of delivery ranged from once per day to 3 x per day and the duration of treatment ranged from 4 weeks to 3 months. No pilot studies were conducted to compare the efficacy of particular dosages, timing, delivery or duration and there is no indication of whether any of these variables are essential for success. Again, preclinical animal models could provide useful insights on these variables.

**DISCUSSION**

Based on recent studies, it is clear that relatively few clinical trials of probiotics for OPC were based on sound \textit{in vitro} experimental data and/or appropriate preclinical animal models of infection. Because of the beneficial immunomodulatory effects of several probiotic strains, we suggest that further research is needed in animal models that recapitulate the specific host immune deficiency, to better target the probiotics to the specific underlying immune-compromising condition of susceptible patients.

It will also be important to further study the mechanisms of inhibition of \textit{Candida} spp. by probiotic organisms and particularly to determine whether these mechanisms are active in the oral environment. Animal models should be used to determine the best methods for delivery of probiotics to the oral cavity before being applied in humans. Molecules with anti-\textit{Candida} activity that are produced by probiotic species must be identified and their activity tested in appropriate animal models. Further, it will be essential to explore immune effects of probiotics both at the local level of the oral mucosa and at the systemic level and to determine how these changes in immune responses impact the susceptibility or severity of OPC.

**AUTHOR CONTRIBUTIONS**

LA researched the literature and wrote and edited the article. AD-B provided guidance and focus and edited the article. Both authors contributed to the article and approved the submitted version.

**FUNDING**

This study was funded by NIH/NIDCR Grant RO1 DE013986 and NIH/NIGMS Grant RO1 GM127909.

**REFERENCES**

1. Lombardi A, Ouanounou A. Fungal infections in dentistry: clinical presentations, diagnosis, and treatment alternatives. \textit{Oral Surg Oral Med Oral Pathol Oral Radiol}. (2020) 130:533–46. doi: 10.1016/j.oooo.2020.08.011
2. Fidel PL. \textit{Candida}-host interactions in HIV disease: implications for oropharyngeal candidiasis. \textit{Adv Dent Res}. (2011) 23:45–9. doi: 10.1177/0022034511399284
3. Brent NB. Thrush in the breastfeeding dyad: results of a survey on diagnosis and treatment. \textit{Clin Pediatr}. (2001) 40:503–6. doi: 10.1177/00992280104000905

4. Gendreau I, Loewy ZG. Epidemiology and etiology of denture stomatitis. \textit{J Prosthodont}. (2011) 20:251–60. doi: 10.1111/j.1534-7560.2011.01098.x
5. Bertolini M, Ranjan A, Thompson A, Diaz PL, Sobue T, Maas K, et al. \textit{Candida albicans} induces mucosal bacterial dysbiosis that promotes invasive infection. \textit{PLoS Pathog}. (2019) 15:e1007717. doi: 10.1371/journal.ppat.1007717
6. Abusleme I, Diaz PL, Freeman AF, Greenwell-Wild T, Brenchley L, Desai JV, et al. Human defects in STAT3 promote oral mucosal fungal and bacterial dysbiosis. \textit{JCI Insight}. (2018) 3:e122061. doi: 10.1172/jci.insight.122061
7. Food and Agricultural Organization/World Health Organization. \textit{Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria}. (2013) 772:47–59.
Acid Bacteria. Cordoba, Argentina (2001). Available online at: https://scholar.google.com/scholar?hl=en&as_sdt=0%2C7&q=Joint$+$FAO%2FVHOS$+$eXpert$+$consultation$+$eS$+$evaluation$+$eS$+$health$+$eS$+$nutrition$+$eS$+$proprieties$+$eS$+$probiotics$+$eS$+$food&btnG=(accessed January 16, 2022).

24. Petti S, Tarsitani G, D’Arca AS. A randomized clinical trial of the effect of probiotics on the treatment of oral candidiasis. *Dermatol Ther.* (2019) 32:e12970. doi: 10.1111/dth.12970.

23. Miyazima TY, Ishikawa KH, Mayer MPA, Samaranayake LP. Probiotics reduce the prevalence of oral Candida in the treatment of oral candidiasis. *BMJ Open.* (2014) 4:e005047. doi: 10.1136/bmjopen-2014-005047.

22. Li D, Li Q, Liu C, Dan H, Zhou Y, et al. Meta-analysis of randomized trials assessing the effects of probiotics on oral health. *J Funct Foods.* (2020) 70:103985. doi: 10.1016/j.jff.2020.103985.

21. Burton JP, Drummond BK, Chilcott CN, Thomson WM, Hale JDF, et al. Influence of the probiotic *Streptococcus salivarius* strain M18 on indices of dental health in children: a randomized double-blind, placebo-controlled trial. *J Dent Res.* (2007) 86:125–30. doi: 10.1177/154405910708600204.

20. Matsubara VH, Wang Y, Bandara HMHN, Mayer MPA, Samaranayake LP. Probiotics as Antifungals in Mucosal Candidiasis. *Clin Infect Dis.* (2016) 62:1143–53. doi: 10.1093/cid/ciw038.

19. Andrade JC, Kumar S, Kumar A, Cernáková L, Rodrigues CF. Application of probiotics in candidiasis management. *Crit Rev Food Sci Nutr.* (2021) 1–16. doi: 10.1080/10408398.2021.1926905.

18. Hatakka K, Ahola AJ, Yli-Knuuttila H, Richardson M, Poussa T, Meurman JH, et al. Probiotics reduce the prevalence of oral Candida in the elderly a randomized controlled trial. *J Dent Res.* (2007) 86:125–30. doi: 10.1177/1544059107078060204.

17. Ishikawa KH, Mayer MPA, Miyazima TY, Matsubara VH, Silva EG, Paula CR, et al. A multispecies probiotic reduces oral candida colonization in denture wearers. *J Prosthodont.* (2015) 24:194–9. doi: 10.1111/jopr.2012.191298.

16. Hu L, Zhou M, Young A, Zhao W, Yan Z. In vivo effectiveness and safety of probiotics on prophylaxis and treatment of oral candidiasis: a systematic review and meta-analysis. *BMJ Oral Health.* (2019) 19:140. doi: 10.1186/s12903-019-0841-2.

15. Ai R, Wei J, Ma D, Jiang L, Dan H, Zhou Y, et al. A meta-analysis of randomized trials assessing the effects of probiotics on oral health in the elderly. *Arch Oral Biol.* (2017) 83:187–92. doi: 10.1016/j.archoralbio.2017.04.030.

14. Chugh P, Dutt R, Sharma A, Bhagat N, Dhar MS, et al. A critical appraisal of probiotics in oral health and disease: the impact of probiotics. *Genes Nutr.* (2011) 6:209–40. doi: 10.1007/s12263-011-0229-7.

13. Andrade JC, Kumar S, Kumar A, Cernáková L, Rodrigues CF. Application of probiotics in candidiasis management. *Crit Rev Food Sci Nutr.* (2021) 1–16. doi: 10.1080/10408398.2021.1926905.

12. Matsubara VH, Silva EG, Paula CR, Ishikawa KH, Nakamae AEM. Treatment with probiotics in experimental oral colonization by Candida albicans in murine model (DBA/2). *Oral Dis.* (2012) 18:260–4. doi: 10.1111/j.1601-0825.2011.01688.x.

11. Wilhelm T, Sequoia J. Probiotics for gastrointestinal conditions: a summary of the evidence. *Am Fam Physician.* (2017) 96:170–8.

10. Gerritsen J, Smidt H, Rijkers GT, de Vos WM. Intestinal microbiota in human health and disease: the impact of probiotics. *Genes Nutr.* (2011) 6:209–40. doi: 10.1007/s12263-011-0229-7.

9. McFarland L. Use of probiotics to correct dysbiosis of normal microbiota follow- ing disease or disruptive events: a systematic review. *BMJ Open.* (2014) 4:e005047. doi: 10.1136/bmjopen-2014-005047.

8. McFarland L. Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: a systematic review. *BMJ Open.* (2014) 4:e005047. doi: 10.1136/bmjopen-2014-005047.

7. Shonyo A, Gottlieb A. Probiotics for oral and vulvovaginal candidiasis: a review. *Dermatol Ther.* (2019) 32:e12970. doi: 10.1111/dth.12970.

6. Santacroce L, Charitos IA, Bottalico L. A successful history: probiotics and oral health. *Caries Res.* (2017) 94:181S–92S. doi: 10.1594/CarRes/64111647.

5. Raja M, Hannan A, Ali K. Association of oral candidal carriage with dental caries in children. *Caries Res.* (2010) 44:272–6. doi: 10.1159/000341675.

4. Fahmetta ML, Klein MI, Colomne PM, Scott-Anne K, Gregoire S, Pai CH, et al. Symbiotic relationship between Streptococcus mutans and Candida albicans synergizes virulence of plaque biofilms *in vivo*. *Infect Immun.* (2014) 82:1968–81. doi: 10.1128/IAI.00087-14.

3. Andrade JC, Kumar S, Kumar A, Cernáková L, Rodrigues CF. Application of probiotics in candidiasis management. *Crit Rev Food Sci Nutr.* (2021) 1–16. doi: 10.1080/10408398.2021.1926905.

2. Matsubara VH, Silva EG, Paula CR, Ishikawa KH, Nakamae AEM. Treatment with probiotics in experimental oral colonization by Candida albicans in murine model (DBA/2). *Oral Dis.* (2012) 18:260–4. doi: 10.1111/j.1601-0825.2011.01688.x.

1. McFarland L. Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: a systematic review. *BMJ Open.* (2014) 4:e005047. doi: 10.1136/bmjopen-2014-005047.
probiotic intake revealed by 16S rRNA sequencing on the IonTorrent PGM platform. *J Biotechnol.* (2014) 190:30–9. doi: 10.1016/j.jbiotec.2014.03.024

48. Dassi E, Ferretti P, Covello G, Speccher A, Migazzi A, Bosco B, et al. The short-term impact of probiotic consumption on the oral cavity microbiome. *Sci Rep.* (2018) 8:2–9. doi: 10.1038/s41598-018-28491-x

49. D’Enfert C, Kaune AK, Alaban LR, Chakraborty S, Cole N, Delavy M, et al. The impact of the fungus-host-microbiota interplay upon *Candida albicans* infections: current knowledge and new perspectives. *FEMS Microbiol Rev.* (2021) 45:fuaa060. doi: 10.1093/femsre/fuaa060

50. Romani L, Zelante T, Palmieri M, Napolioni V, Picciolini M, Velardi A, et al. The cross-talk between opportunistic fungi and the mammalian host via microbiota’s metabolism. *Semin Immunopathol.* (2015) 37:163–71. doi: 10.1007/s00281-014-0464-2

51. Sparber F, LeibundGut-Landmann S. Interleukin 17-mediated host defense against *Candida albicans*. *Pathogens.* (2015) 4:606–19. doi: 10.3390/pathogens4030606

52. Conti HR, Bruno VM, Childs EE, Daugherty S, Hunter JP, Mengesha BG, et al. IL-17 Receptor signaling in oral epithelial cells is critical for protection against oropharyngeal candidiasis. *Cell Host Microbe.* (2016) 20:606–17. doi: 10.1016/j.chom.2016.10.001

53. Zelante T, Iannitti RG, Cunha C, DeLuca A, Giovannini G, Pieraccini G, et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. *Immunity.* (2013) 39:372–85. doi: 10.1016/j.immuni.2013.08.003

54. Lebeer S, Vanderleyden J, de Keersmaecker SCJ. Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. *Nat Rev Microbiol.* (2010) 8:171–84. doi: 10.1038/nrmicro2297

55. Marranzino G, Villena J, Salva S, Alvarez S. Stimulation of macrophages by immunobiotic *Lactobacillus* strains: influence beyond the intestinal tract. *Microbiol Immunol.* (2012) 56:771–81. doi: 10.1111/j.1348-0421.2012.00495.x

56. Matsubara VH, Ishikawa KH, Ando-Sugimuto ES, Bueno-Silva B, Nakamae AEM, Mayer MPA. Probiotic bacteria alter pattern-recognition receptor expression and cytokine profile in a human macrophage model challenged with *Candida albicans* and lipopolysaccharide. *Front Microbiol.* (2017) 8:2280. doi: 10.3389/fmicb.2017.02280

57. Rizzo A, Losacco A, Carratelli CR. *Lactobacillus* crispatus modulates epithelial cell defense against *Candida albicans* through Toll-like receptors 2 and 4, interleukin 8 and human β-defensins 2 and 3. *Immunol Lett.* (2013) 156:102–9. doi: 10.1016/j.imlet.2013.08.013

58. Dongari-Bagtzoglou A, Kashleva H. Development of a highly reproducible three-dimensional organotypic model of the oral mucosa. *Nat Protoc.* (2006) 1:2012–8. doi: 10.1038/nprot.2006.323

59. Tang S, Moyses D, Richardson J, Blagojevic M, Naglik J. Epithelial discrimination of commensal and pathogenic *Candida albicans*. *Oral Dis.* (2016) 22:114–9. doi: 10.1111/odi.12395

60. Lee X, Vergara C, Lozano CP. Severity of Candida-associated denture stomatitis is improved in institutionalized elders who consume *Lactobacillus rhamnosus* SP1. *Aust Dent J.* (2019) 64:229–36. doi: 10.1111/adj.12692

61. Saxelin M, Pessi T, Salminen S. Fecal recovery following oral administration of *Lactobacillus Strain GG* (ATCC 53103) in gelatin capsules to healthy volunteers. *Int J Food Microbiol.* (1995) 25:199–203. doi: 10.1016/0168-1605(94)00091-J

62. Szajewska H, Kołodziej M, Gieruszczak-Białek D, Skórka A, Ruszczyński M, Shamir R. Systematic review with meta-analysis: *Lactobacillus rhamnosus* GG for treating acute gastroenteritis in children – a 2019 update. *Aliment Pharmacol Ther.* (2019) 49:1376–84. doi: 10.1111/apt.15267

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Archambault and Dongari-Bagtzoglou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.